Related Experiment Video

Updated: Apr 17, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer

Seiji Mabuchi1, Hiromasa Kuroda1, Ryoko Takahashi1

  • 1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

Gynecologic Oncology
|February 14, 2015
PubMed

Insights

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is crucial for ovarian cancer progression. Targeting this pathway offers therapeutic potential, but challenges remain in clinical development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The PI3K/AKT/mTOR pathway is integral to tumor malignant transformation, growth, proliferation, and metastasis.
  • This pathway is frequently activated in ovarian cancers, particularly clear cell carcinoma and endometrioid adenocarcinoma.
  • Its frequent activation makes the PI3K/AKT/mTOR pathway a promising target for ovarian cancer therapy.

Purpose of the Study:

  • To review recent advancements in understanding the PI3K/AKT/mTOR pathway in ovarian cancer.
  • To discuss the therapeutic potential of targeting this pathway for ovarian cancer treatment.
  • To identify obstacles hindering the clinical development of PI3K/AKT/mTOR inhibitors.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of molecular mechanisms underlying PI3K/AKT/mTOR pathway activation in ovarian cancer.
  • Evaluation of current therapeutic strategies and clinical trial data.

Main Results:

  • Preclinical data strongly support PI3K/AKT/mTOR pathway involvement in ovarian cancer.
  • Various inhibitors targeting the PI3K/AKT/mTOR pathway are in clinical development.
  • The review highlights progress in understanding pathway dysregulation and therapeutic approaches.

Conclusions:

  • The PI3K/AKT/mTOR pathway is a key driver in ovarian cancer, offering a viable therapeutic target.
  • Targeted therapies show promise but face challenges in clinical translation.
  • Further research is needed to overcome development hurdles and optimize treatment efficacy.
Keywords:
AKTOvarian cancerPI3KmTORmTORC1mTORC2

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.6K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K